[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alpha Tau Medical Ltd Cl A (DRTS)

Alpha Tau Medical Ltd Cl A (DRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Can Alpha Tau Medical Answer What Happens When Trial Data Arrives Before Revenue Does?

Alpha Tau Medical Ltd. (DRTS) is scheduled to report Q1 2026 earnings before the market opens on Monday, May 18, with a conference call set for Tuesday, May 19 at 4:00 PM ET. The company faces a critical test as it seeks to demonstrate progress following its landmark Japanese regulatory approval while managing investor expectations around its expanding clinical trial portfolio. With the stock trading at $10.36 and showing strong momentum into the release, the question is whether Alpha Tau can deliver results that justify the recent rally and support its ambitious global expansion plans.

Fundamentals

See More
  • Market Capitalization, $K 911,784
  • Shares Outstanding, K 88,010
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,630 K
  • EBIT $ -9 M
  • EBITDA $ -41 M
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.88

Options Overview Details

View History
  • Implied Volatility 99.12% (+1.34%)
  • Historical Volatility 89.59%
  • IV Percentile 23%
  • IV Rank 2.97%
  • IV High 812.34% on 12/09/25
  • IV Low 77.26% on 05/05/26
  • Expected Move (DTE 32) 2.09 (20.18%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 3,122
  • Volume Avg (30-Day) 970
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 12,045
  • Open Int (30-Day) 8,820
  • Expected Range 8.27 to 12.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 2
  • High Estimate $-0.12
  • Low Estimate $-0.13
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.15 +44.90%
on 04/29/26
10.81 -4.16%
on 05/15/26
+2.48 (+31.47%)
since 04/15/26
3-Month
6.10 +69.84%
on 03/09/26
10.81 -4.16%
on 05/15/26
+3.15 (+43.69%)
since 02/13/26
52-Week
2.78 +272.66%
on 05/16/25
10.81 -4.16%
on 05/15/26
+7.40 (+250.12%)
since 05/15/25

Most Recent Stories

More News
Can Alpha Tau Medical Answer What Happens When Trial Data Arrives Before Revenue Does?

Barchart Research What to Expect from DRTS Earnings DRTS Generated May 15, 2026 Current Price $10.36 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 4.28% Can Alpha Tau Medical Answer What...

DRTS : 10.36 (-0.48%)
Can Alpha Tau Medical Answer What Happens When Trial Data Arrives Before Revenue Does?

Barchart Research What to Expect from DRTS Earnings DRTS Generated May 15, 2026 Current Price $10.36 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 4.28% Can Alpha Tau Medical Answer What...

DRTS : 10.36 (-0.48%)
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study

Alpha Tau Medical (NASDAQ:DRTS) presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical...

DRTS : 10.36 (-0.48%)
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since treatment...

DRTS : 10.36 (-0.48%)
DRTSW : 2.15 (+7.77%)
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha...

DRTS : 10.36 (-0.48%)
DRTSW : 2.15 (+7.77%)
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA modular...

DRTS : 10.36 (-0.48%)
DRTSW : 2.15 (+7.77%)
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute

First patient ever treated with Alpha DaRT for pancreatic cancer in Italy, under a clinical study conducted at the world-renowned Pancreas Institute of the University of Verona The study is the first...

DRTS : 10.36 (-0.48%)
DRTSW : 2.15 (+7.77%)
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

- Abstract from trial evaluating Alpha DaRT ® in combination with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma selected for podium...

DRTS : 10.36 (-0.48%)
DRTSW : 2.15 (+7.77%)
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

- 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT ® in pancreatic adenocarcinoma - - Favorable safety profile observed,...

DRTS : 10.36 (-0.48%)
DRTSW : 2.15 (+7.77%)
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

- Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world’s largest and most prestigious medical oncology conference - - Pooled analysis combines safety...

DRTS : 10.36 (-0.48%)
DRTSW : 2.15 (+7.77%)

Business Summary

Alpha Tau Medical Ltd. is a medical device company. It focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha Tau Medical Ltd., formerly known as Healthcare Capital Corp., is based in JERUSALEM.

See More

Key Turning Points

3rd Resistance Point 11.39
2nd Resistance Point 11.10
1st Resistance Point 10.73
Last Price 10.36
1st Support Level 10.07
2nd Support Level 9.78
3rd Support Level 9.41

See More

52-Week High 10.81
Last Price 10.36
Fibonacci 61.8% 7.74
Fibonacci 50% 6.79
Fibonacci 38.2% 5.85
52-Week Low 2.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.